

Please cancel Claims 1-65 without prejudice to applicants' right to file divisional applications directed to the subject matter thereof. Please insert new claims 66-130.

REMARKS

Restriction under 35 U.S.C. 121

Claims 1-65 have been cancelled without prejudice. New claims 66-130 are pending.

1. The Office has identified six inventions as follows:

- I. Claims 1-11 (in part) , and 13-65 (in part), drawn to compounds where A¹ represents a pyridinyl group (class 546, subclass various).
- II. Claims Claims 1-11 (in part) , and 13-65 (in part), drawn to compounds where A¹ represents a naphthyridinyl group(class 546, subclass various).
- III. Claims 1-11 (in part) , and 14-65 (in part), drawn to compounds where A¹ represents a pyrido-oxazinyl group (class 544, subclass various).
- IV. Claims 1-11 (in part) , and 13-65 (in part), drawn to compounds where A¹ represents a pyrazolyl or imidazolyl group (class 548, subclass various).
- V. Claims 1-11 (in part) , 14 (in part), and 16-65 (in part) drawn to compounds where A¹ represents others (class, subclass various).
- VI. Claim 12, drawn to intermediates of formula 2 (class 562, subclass various).

2. Applicants elect Group I.


3. Applicants submit that the election of Group I is without prejudice to Applicants' right to file divisional applications directed to the subject matter not contained therein.

Description of New Claims

Applicants submit claims 66-130:


In claim 66: To comply with the election under requirement for restriction, A has been defined as pyridinyl, and non-elected matter has been removed without prejudice. The term $(CH_2)_n$ has been changed to $(CH_2)_m$ and the following definition of n changed to m, which more specifically points out the invention.

In claim 67: To comply with the election under requirement for restriction, A¹ has been defined as




Non-elected matter has been removed without prejudice. Claim dependency has been added to reflect the addition of new claims 66-130.

In claim 68: To comply with the provisional election under requirement for restriction, A¹ has been defined as



, and non-elected matter has been removed without prejudice. R^{79} has been labeled as such to more specifically point out the invention. Claim dependency has been added to reflect the addition of new claims 66-130.

In claim 69: To comply with the election under requirement for restriction, non-elected matter has been removed without prejudice. The linkage A¹-Z² has been defined as selected




R^{80} , R^{81} and R^{82} have been labeled as such to more specifically point out the invention. Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 70: Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 71: Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 72: R^{83} , R^{84} , R^{85} , R^{86} , R^{87} , R^{88} , R^{89} , R^{90} , R^{91} , R^{92} , X^7 , and X^8 have been labeled as such to more specifically point out and clarify the invention. Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 73: To comply with the election under requirement for restriction, non-elected matter has been removed without prejudice. A^1 has been defined as




R^{93} and R^{94} have been labeled as such to more specifically point out and clarify the invention. Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 74: Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 75: Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 76: The reference to the definition of R^k has been removed without prejudice to conform with proper claim construction. Claim dependency has been changed to reflect the addition of new claims 66-130.


In claim 77: To comply with the election under requirement for restriction, non-elected matter has been removed without prejudice. A^1 has been defined as



Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 78: Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 79: To comply with the election under requirement for restriction, non-elected matter has been removed without prejudice. A¹ has been defined as



R⁹⁵ and R⁹⁶ have been labeled as such to more specifically point out and clarify the invention. Claim dependency has been changed to reflect the addition of new claims 66-130.

In claim 80: To comply with the election under requirement for restriction, non-elected matter has been removed without prejudice (The following were removed: (2-{3-Fluoro-4-[3-(1-*H*-pyrazol-3-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid, (1-(2,3-Dihydro-benzofuran-6-yl)-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid, (1-Benzo[1,3]dioxol-5-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid, (1-Isloxazol-3-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid, (1-Isloxazol-5-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid, (1-Oxazol-5-yl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid, (2-{4-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-1-thiazol-5-yl-cyclopropyl)-acetic acid, (2-{4-[3-(1-*H*-Imidazol-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid, (2-{3-Fluoro-4-[3-(1-*H*-imidazol-2-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid, (2-{3-Fluoro-4-[3-(3-*H*-imidazol-4-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid, (2-


{4-[3-(3-*H*-Imidazol-4-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid, (2-{4-[3-(1-*H*-Pyrazol-3-ylamino)-propoxy]-phenyl}-cyclopropyl)-acetic acid, (1-Methyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid, (1-Methoxymethyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid, (1-Methanesulfonylmethyl-2-{4-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-phenyl}-cyclopropyl)-acetic acid. Claim dependency has been changed to reflect the addition of new claims 66-130.

In claims 81-130: Claim dependency has been changed to reflect the addition of new claims 66-130.

In view of the foregoing amendments, it is respectfully submitted that all claims now active in the present application are in condition for allowance. Therefore, passage of the application and claims to issue is respectfully requested.

No further fee or petition is deemed to be necessary. However, should any further fee be needed, please charge our Deposit Account No. 19-1025, and deem this paper to be the required petition.

Respectfully submitted,



Rachel A. Polster

Registration No. 47,004

Telephone: 314-694-7354

Pharmacia Corp. Patent Dept.

Patent Department Central

800 N. Lindbergh Blvd., Mail Zone O4E

St. Louis, MO 63167